Stay updated on Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial

Sign up to get notified when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    The study has expanded to include 143 locations and has been updated from revision v2.9.7 to v2.10.0.
    Difference
    0.2%
    Check dated 2024-07-22T14:43:02.000Z thumbnail image
  6. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.0%
    Check dated 2024-07-16T10:06:17.000Z thumbnail image
  7. Check
    23 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.6 from v2.9.5.
    Difference
    0.0%
    Check dated 2024-07-03T19:52:56.000Z thumbnail image
  8. Check
    30 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the webpage content.
    Difference
    0.0%
    Check dated 2024-06-27T11:17:48.000Z thumbnail image
  9. Check
    31 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.
    Difference
    0.0%
    Check dated 2024-06-26T09:51:48.000Z thumbnail image
  10. Check
    32 days ago
    Change Detected
    Summary
    The value 'Show more Revision: v2.9.0' has been updated to 'MedlinePlus related topics: Thyroid Cancer, Thyroid Diseases, Genetic and Rare Diseases Information Center resources: Thyroid Cancer, Medullary Neuroendocrine Tumor, Neuroepithelioma, Drug Information available for: Thyroid, Vandetanib, Cabozantinib, Selpercatinib, FDA Drug and Device Resources'
    Difference
    40%
    Check dated 2024-06-25T08:56:19.000Z thumbnail image

Stay in the know with updates to Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.